Positive Clinical Trial Results Of Investigational Thrombocytopenia Agent
Sat, 16 Dec 2006 11:00 PM EST
... AKR-501 is a promising member of a new class of agents called, "TPO receptor agonists" that is now in Phase II clinical development. It is an investigational orally administered drug being developed by AkaRx, Inc. intended to mimic the biologic effect of thrombopoietin, a growth factor that stimulates production of platelets. [click link for full article] ...
Related Topics
- Clinical Trials
- Thrombocytopenia
- Agent Orange
- Chemical Agents
- Pharmacology
- Trastuzumab
- Psychopharmacology
- Tarceva
- Autoimmune Thrombocytopenia Purpura
- Immune Thrombocytopenia Purpura
- Clinical Growth Charts
- Tb
- Bevacizumab Injection
- Riot Control Agents
- Crohn's Disease
- Pancreatic Cancer
- Brain injury that results in physical, emotional, or intellectual changes or deficits
- Select Agent Program
- Delta agent (Hepatitis D)
- Patient Issues

Not Signed In -

